argenx NV ADR (ARGX)vsNervGen Pharma Corp. (NGEN)
ARGX
argenx NV ADR
$781.72
+0.73%
HEALTHCARE · Cap: $48.85B
NGEN
NervGen Pharma Corp.
$3.63
-3.20%
HEALTHCARE · Cap: $311.58M
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 30.5% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 61/100 (C+).
ARGX
Buy61
out of 100
Grade: C+
NGEN
Avoid17
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+60.6%
Fair Value
$2119.32
Current Price
$781.72
$1337.60 discount
Intrinsic value data unavailable for NGEN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Strong operational efficiency at 27.4%
No standout strengths identified
Areas to Watch
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 165.3x book value
Earnings declined 31.9%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : NGEN
NGEN has a balanced fundamental profile.
Bear Case : ARGX
The primary concerns for ARGX are Piotroski F-Score, P/E Ratio, Price/Book. A P/E of 40.0x leaves little room for execution misses.
Bear Case : NGEN
The primary concerns for NGEN are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while NGEN is a value play — different risk/reward profiles.
NGEN carries more volatility with a beta of 0.99 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (61/100 vs 17/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
NervGen Pharma Corp.
HEALTHCARE · BIOTECHNOLOGY · USA
Nanogen Inc (NGEN) is a cutting-edge biotechnology company dedicated to advancing molecular diagnostic technologies aimed at improving patient outcomes through innovative genomic analysis solutions. The firm specializes in the development and commercialization of products tailored to complex disease targets, utilizing its proprietary platforms to deliver precise and timely diagnostics. With a robust focus on research and development, Nanogen is poised to expand its portfolio and drive growth in the dynamic diagnostic market, aligning with the industry's shift toward personalized medicine and the increasing demand for sophisticated diagnostic tools.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?